Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (March 2024)
36 slides from Volitionrx's investor presentation, March 2024
Slide 1: Corporate Deck
Corporate Deck March 2024 Property Propertyof Volition©©2024 ofVolition 2024 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Our mission is to save lives and improve outcomes
Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Property Propertyof Volition©©2024 ofVolition 2024 Slide 3
Slide 4: Who we are
Who we are • Diagnostic company focusing on epigenetic markers • Epigenetics = on top of, or in addition to the genome • Disease areas – global killers: Cancer, Sepsis. • Human and Veterinary use cases: • Screening • Monitoring (disease progression and response to treatment) • Revenue focus on veter
Slide 5: What sets us apart?
What sets us apart? • Our tests are simple, low-cost accessible routine blood tests • Platform agnostic, can be adapted to any diagnostic workflow • Manual, Reference Lab, Specialist Lab and Point of Care Six Hours <10 minutes 45 minutes 20 minutes <15 minutes • Our Intellectual Property • 79 patent
Slide 6: Commercial Strategy - Licensing
Commercial Strategy - Licensing Overall strategy • R&D conducted by Volition and its research partners • Volition monetizes IP with upfront payments, milestone payments, royalties and sales of key components • Commercialisation via global players and in fragmented markets, regional companies Partner
Slide 7: Our Technologies
Our Technologies Chromatin Chromosome Nucleosome Cancer and cell death cause chromatin CTCF fragmentation Sequence only present on CTCF in cancer Property of Volition© 2024 Slide 7
Slide 8: Nu.Q Vet Cancer Test
Nu.Q® Vet Cancer Test Property of Volition Veterinary Diagnostics Development© 2024 Slide 8
Slide 9: Early detection
Number of pet dogs in the US1 Early detection can lead to improved treatment outcomes Approximately “Healthy” animals can tolerate 84 million treatment better Treatment can then often be more cost-effective Early detection also opens up Nearly 50% opportunities for therapeutic product of dogs over t
Slide 10: Clinical Evidence
Clinical Evidence Peer-reviewed and published case series1. of 662 dogs (134 healthy and 528 with cancer) 7 common cancers were evaluated in this study Lymphoma Malignant melanoma Hemangiosarcoma Mast cell tumors Osteosarcoma Histiocytic sarcoma Soft tissue sarcoma 1. Wilson-Robles, H.M., Bygott, T.
Slide 11: Revenue 2023
Revenue 2023 Kits and Components $475,000 Revenue 194% Growth over for over 58,000 tests Recorded 2023 Prior Year sold in 2023 Property of Volition Veterinary Diagnostics Development© 2023 Slide 11
Slide 12: Milestones and Progress
Milestones and Progress • Launched with IDEXX in the U.S Jan ‘23 • Tech Transfer to elementi+ • Launched in UK & Ireland Nov ‘23 completed Dec ‘23 • Launch April ‘24 • Launching in Japan SOON • Launched in Portugal Nov ‘22 • Launched in • Launched in Taiwan Nov ‘23 Singapore Nov ‘23 Property of Voli
Slide 13: Launching April 2024
Launching April 2024 Exclusive agreement with Heska providing in- hospital access to Nu.Q® $10M upfront and $13M milestone payments received to-date. $5M remaining Launch expected APRIL 2024 Ongoing revenue from the purchase of kits and key components Property of Volition Veterinary Diagnostics Deve
Slide 14: Launching April 2024
Launching April 2024 Rapid (<10 mins) Accurate Cost effective Allowing veterinarian to make informed clinical decisions quickly – whilst the patient is still in clinic Property of Volition Veterinary Diagnostics Development© 2023 Slide 14
Slide 15: Development Pipeline
Development Pipeline Monitoring Cancer in NETosis Application Cats Property of Volition Veterinary Diagnostics Development© 2024 Slide 15
Slide 16: Sepsis & Thrombosis
Sepsis & Thrombosis Property of Volition© 2023 2024 Slide 16
Slide 17: Property of Volition © 2024 Slide 17
Property of Volition© 2024 Slide 17
Slide 18: Sepsis – current challenges
Sepsis – current challenges • The rapid identification and treatment of sepsis significantly improves patient outcomes and reduces complications and long- term morbidity1. • The risk of death from sepsis increases by 7.6% for each hour of delay in appropriate antibiotic therapy2. • CURRENT methods o
Slide 19: Study Overviews
Study Overviews • Range from prospective, blinded, longitudinal studies to retrospective analyses of high-quality biobanks from respected groups. • Large Cohort sizes – ranging from 250 to 1000 patients • Total samples for analysis ~ 14,000 • Covering ED and ICU • KEY Outcome measures (correlation w
Slide 20: Key Milestones
Key Milestones • Initiate early access of current CE-IVD i10 product in EU with IDS & Centers of Excellence and other targeted clients in EU (IVDD plan), US (RUO) and Asia (RUO): H1 2024. • Demonstrate clinical utility of our current product using product gen1: June 2024. • Develop product gen2 (thr
Slide 21: Early cancer detection by plasma CTCF transcription factor analysis
Early cancer detection by plasma CTCF transcription factor analysis Poster Presentation ESMO 2023 – see website for details Property of Volition© 2024 Slide 21
Slide 22: Liquid biopsy for ctDNA
Liquid biopsy for ctDNA Is like looking for a needle in a haystack… 99.9% 0.1% ...and the needle is made of hay! Nucleosomes and ctDNA released into the blood Property of Volition© 2024 Slide 22
Slide 23: Liquid biopsy for ctDNA
Liquid biopsy for ctDNA CTCF 99.9% 0.1% Then you can do a You need to physically separate PCR test as simple some or all of the ctDNA as a COVID-19 test (nearly) Property of Volition© 2024 Slide 23
Slide 24: Novel wet chemistry pathway for ctDNA analysis
Novel wet chemistry pathway for ctDNA analysis NEW wet chemistry pathway PCR of CTCF Sample sequences ChIP collection uniquely present (Capture) in cancer First novel wet chemistry pathway for liquid biopsy First report of plasma TF-ChIP (Capture) Property of Volition© 2024 Slide 24
Slide 25: Proof of principle data presented ESMO 2023
Proof of principle data presented ESMO 2023 • A single qPCR assay discovered on leukemia detected 61% of leukemia cases at 98% specificity • Adding a second qPCR detected 74% of leukemia cases at 96% specificity • Another 2-qPCR assay detected 77% of colorectal cancer cases at 92% specificity • The
Slide 26: What's next?
What’s next? • Cancer specific abstracts and posters at conferences throughout 2024 (already completed Prostate, Lung and Liver, with CRC and breast to come in Q2) • Clinical Paper submission, peer review and publication • Development of specific biomarkers for Lung, CRC, Prostate, Breast and Liver
Slide 27: Comparison ChIP/PCR with traditional NGS/ctDNA assays
Comparison ChIP/PCR with traditional NGS/ ctDNA assays Traditional NGS/ ctDNA assay ChIP/PCR • Cost >$1000 • ~$100 • Too complex to be fully automated • Can be automated • High technology labs only • Any hospital lab • Turnaround - days or weeks • Turnaround 1 day (less if automated) • Library prepa
Slide 28: Summary & Financial Update
Summary & Financial Update Property Propertyof Volition©©2024 ofVolition 2024 Slide 28
Slide 29: Summary
Summary • Diagnostic company focusing on epigenetic markers • Epigenetics = on top of, or in addition to the genome • Disease areas – global killers: Cancer, Sepsis. • Human and Veterinary use cases: • Screening • Monitoring (disease progression and response to treatment) • Revenue focus on veterina
Slide 30: Key Financials Third Quarter 2023
Key Financials Third Quarter 2023 NYSE American Market: VNRX Market Cap: $63m* 52-week range: $0.55-$2.10* Cash used in operating activities:12-month average ~$2.6m/mth** Cash-on-hand: ~$20.7m*** * As of Mar 20, 2024 **As of Dec 31, 2023, excluding milestone payments ***As of 31 Dec, ‘23 Property Pr
Slide 31: Nu.Q Vet Cancer Test Opportunity Simulation
Nu.Q® Vet Cancer Test Opportunity Simulation1. 240 $225m 220 200 *Not revenue guidance and not indicative of the 180 Reference Lab to POC market split & margin Revenue 160 $150m guidance. 140 Opportunity* ($millions) 120 100 80 $75m 60 ~ Underlying Burn Rate 40 $38m (excluding milestone payments) $2
Slide 32: Questions?
Questions? Thank you for your interest in Volition. For more details, please visit www.volition.com Property Propertyof Volition©©2024 ofVolition 2024 Slide 32
Slide 33: The Team
The Team Property Propertyof Volition©©2024 ofVolition 2024 Slide 33
Slide 34: Executive Team
Executive Team Dill Faulkes PhD, Executive Chairman - Dill Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States. As the Founder and one of the Benefactors of the Dill Faulkes Educat
Slide 35: Executive Team
Executive Team Andrew Retter MBBS, MRCP, FRCPath (Haem), DICM, FFICM , Chief Medical Officer - Retter obtained his medical degree from St. George’s Hospital Medical School in 2001 and completed his postgraduate training in hematology and intensive care medicine at St. Thomas’ Hospital in London. He
Slide 36: Executive Team
Executive Team Nick Plummer, Group General Counsel - Nick has over 25 years experience as a corporate and commercial lawyer, specializing in healthcare. Nick qualified with the international law firm, Ashurst, and has since worked in-house for companies such as Novacyt, Ark Therapeutics PLC and Path